Clinical Trial Update: The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bevacizumab as a modulator of wound healing after trabeculectomy for glaucoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Moorfields Eye Hospital NHS Foundation Trust | Conditions: Glaucoma | Phase 3 | Status: COMPLETED